BioLight Israeli Life Sciences Investments Ltd. to Webcast, Live, at RetailInvestorConferences.com on September 12th

NEW YORK, Sept. 10, 2013 /PRNewswire/ -- BioLight Israeli Life Science Investments Ltd (TASE: BOLT), a unique Biomedical firm engaged in the management and commercialization of technology in cancer diagnostics and ophthalmology, today announced that Suzana Nahum-Zilberberg, CEO will present at RetailInvestorConferences.com.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

About BioLight Israeli Life Sciences Investments Ltd:

BioLight (TASE: BOLT) directly invests in, manages and commercializes biomedical innovations by focusing on groups, or 'clusters,' of technologies that explore different aspects of the same medical condition.  BioLight's two current clusters include ophthalmology, through its 100% owned subsidiary XL Vision; and cancer diagnostics via its 29% ownership of Micromedic (TASE:  MCTC).  BioLight trades on the Tel-Aviv Stock Exchange under the symbol BOLT.  Additional information is available at www.bio-light.co.il

About RetailInvestorConferences.com:

Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

SOURCE BioLight Israeli Life Science Investments Ltd